Targeting cancer-specific mutations by T cell receptor gene therapy
- 1 April 2015
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 33, 112-119
Abstract
No abstract availableKeywords
Funding Information
- NIH (P01-CA97296, R01-CA22677, R01-CA37156)
This publication has 76 references indexed in Scilit:
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaJournal of Clinical Oncology, 2013
- MHC Multimer-Guided and Cell Culture-Independent Isolation of Functional T Cell Receptors from Single Cells Facilitates TCR Identification for ImmunotherapyPLOS ONE, 2013
- Virus-induced hepatocellular carcinomas cause antigen-specific local toleranceJournal of Clinical Investigation, 2013
- In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene censusOncoImmunology, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growthOncoImmunology, 2012
- Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome dataProceedings of the National Academy of Sciences, 2011
- Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsivenessJournal of Experimental Medicine, 2008